Abstract.
The aim of the study was to investigate the safety of an HIV-1 gp160 plasmid vaccine. Four asymptomatic HIV-1-infected subjects with CD4+ lymphocyte counts >500/μl were injected with four times 400 μg of HIV-1 modified gp160 env and rev coding DNA vaccine at 0, 4, 10 and 28 weeks. Safety parameters, including autoimmune antibodies as well as CD4+/CD8+ cell counts and HIV-1 plasma concentrations, were monitored for 52 weeks after the first vaccine application. Follow-up data for more than 3 years are now available. The DNA vaccine proved to be safe and, specifically, did not induce anti-DNA autoimmune antibodies. Vaccination had no long-term effects on the CD4+/CD8+ lymphocyte counts, plasma HIV-1 RNA concentrations or disease progression. The present data supplement published data from Philadelphia, USA, where a dose-escalating study (30–300 μg) with the same HIV-1 DNA vaccine was performed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Electronic Publication
Rights and permissions
About this article
Cite this article
Weber, R., Bossart, W., Cone, R. et al. Phase I Clinical Trial with HIV-1 gp160 Plasmid Vaccine in HIV-1-Infected Asymptomatic Subjects. Eur J Clin Microbiol Infect Dis 20, 800–803 (2001). https://doi.org/10.1007/s100960100578
Published:
Issue Date:
DOI: https://doi.org/10.1007/s100960100578